Verenium: Analyst Highlights Risk of Plant Delay

Verenium (Cambridge, MA) a biotech start up, faces the risk of a delay in the construction of its planned commercial cellulosic ethanol facility as well as risks to its enzymes business, says Laurence Alexander, an analyst with Jefferies & Co. (New York), in a recent report. Alexander suggests that when looking at Verenium as an investment option, that there are “better risk-rewards available elsewhere.” Alexander’s report follows a recent meeting with Verenium’s president and CEO Carlos Riva, and CFO James Levine.   Issues...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers